Therapy-associated risk decision making in individuals with multiple system atrophy and Parkinson’s disease, THE YAMSA TRIAL
Objective: This study aimed to quantify the risk willingness of patients suffering from the α-synucleinopathies multiple system atrophy (MSA) and Parkinson's Disease (PD) and identify…Preliminary Report on Neuromelanin-Sensitive MRI Signal change after Allogeneic Bone marrow-derived Mesenchymal Stem Cells therapy: Phase IIa double-blind, randomized controlled trial
Objective: To select the most effective number of repeat doses of mesenchymal stem cells (MSC) delivered intravenously to slow the progression of Parkinson’s disease (PD).…Multicenter, randomized, placebo-controlled, double-blind, parallel-group proof-of-concept study of lixisenatide in patients with early Parkinson’s disease (PD): the LIXIPARK trial (NCT03439943)
Objective: To evaluate the “disease-modifying” effect of lixisenatide as adjunct to antiparkinsonian medications in patients with early PD. Background: Lixisenatide, a glucagon-like peptide 1 receptor…Functional brain network alterations in the prodromal phase of X-linked dystonia-parkinsonism
Objective: To determine whether functional connectivity changes are already present in non-manifesting carriers (NMCs) of the TAF1 gene mutation causing X-linked dystonia-parkinsonism (XDP). Background: XDP…The Critical Path for Parkinson’s Consortium approach to developing consensus recommendations for neuroimaging biomarkers appropriate for use in Parkinson’s disease drug development
Objective: To develop consensus recommendations for neuroimaging biomarkers suitable for use in Parkinson’s disease (PD) drug development. Background: Given the anticipated rise in PD prevalence…Small Molecule Inhibitors for Precise Inhibition of α-Synuclein Oligomer Generation in Parkinson’s Disease (PD)
Objective: To develop small molecule therapeutics for PD that inhibit production of toxic α-synuclein oligomers and reduce aggregate formation, targeting the molecular mechanisms at the…Rasagiline in Chinese patients with early-stage parkinson’s disease: a randomized, double-blind, placebo-controlled, delayed-start trial
Objective: Objective: This randomized, double-blind, placebo-controlled, delayed-start trial aimed to investigate the efficacy in symptom improvement and disease-modifying effect of rasagiline for Chinese patients with…Preliminary Report on the efficacy of Allogeneic Bone marrow-derived Mesenchymal Stem Cells as a disease-modifying therapy for idiopathic Parkinson’s disease: Phase IIa double-blind, randomized controlled trial.
Objective: To select the safest and most effective number of repeat doses of allogeneic mesenchymal stem cells (MSC) delivered intravenously to slow the progression of…AAV5-miHTT gene therapy mediates sustained mutant huntingtin lowering in brain and cerebrospinal fluid of Huntington’s disease minipigs up to 5 years
Objective: Our objective is to assess long-term safety of and durability of an adeno-associated viral vector serotype 5 encoding an engineered miRNA (AAV5-miHTT) targeting human…Funding and Sustainability Challenges in Multi-Arm Multi-Stage Clinical Trials in Parkinson Disease
Objective: The Edmond J Safra Accelerating Clinical Trials in Parkinson Disease (PD) initiative (EJS ACT-PD) aims to accelerate the identification of disease modifying treatment for…
- « Previous Page
- 1
- 2
- 3
- 4
- 5
- 6
- …
- 16
- Next Page »